Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283360 | 0.98 | TDP1 (0.71) | TDP1L3MBTL1MEN1KMT2ACES1 | |
| SCHEMBL2054495 | 0.97 | TDP1 (0.73) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL6283135 | 0.95 | TDP1 (0.66) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL6284063 | 0.87 | MEN1 (0.56) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL29418113 | 0.86 | ALDH1A1 (0.67) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL45324 | 0.86 | ALDH1A1 (0.67) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL6283369 | 0.86 | TDP1 (0.58) | TDP1L3MBTL1MEN1KMT2ACASP3 | |
| SCHEMBL6284376 | 0.86 | TDP1 (0.58) | TDP1L3MBTL1MEN1KMT2ACASP3 | |
| SCHEMBL9220253 | 0.85 | TDP1 (0.76) | TDP1L3MBTL1CASP3 | |
| SCHEMBL23731163 | 0.84 | CES1 (0.68) | TDP1L3MBTL1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | TDP1 1772/4885L3MBTL1 1502/4885MEN1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.